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The hearts of lower vertebrates such as fish and salamanders display scarless
regeneration following injury, although this feature is lost in adult mammals.
The remarkable capacity of the neonatal mammalian heart to regenerate
suggests that the underlying machinery required for the regenerative process
is evolutionarily retained. Recent studies highlight the epicardial covering of
the heart as an important source of the signalling factors required for the
repair process. The developing epicardium is also a major source of cardiac
fibroblasts, smooth muscle, endothelial cells and stem cells. Here, we examine
animal models that are capable of scarless regeneration, the role of the epicar-
dium as a source of cells, signallingmechanisms implicated in the regenerative
process and how these mechanisms influence cardiomyocyte proliferation.
We also discuss recent advances in cardiac stem cell research and potential
therapeutic targets arising from these studies.1. Introduction
An emerging concept in cardiovascular biology is that the mammalian myo-
cardium has the potential to regenerate; however, the repair processes are
insufficient to address the extensive damage caused by a cardiac insult such as
myocardial infarction (MI). MI culminates in severe ischaemic damage to the sur-
rounding tissue with, in some cases, the loss of up to a billion cardiomyocytes
(CMs) [1,2]. This results in invasion of immune cells and myofibroblasts promot-
ing scar formation [3,4]. With many advances in medical treatment, the mortality
rate post-MI has decreased [5,6]; however, this has resulted in a rise in the number
of patients that now present with heart failure [7–9]. For these reasons, research
is now focused on enhancing the existing repair processes to improve cardiac
function and to prevent the advent of heart failure. One approach is to study
animal models that undergo full cardiac regeneration and extrapolate these
observations to the adult human heart.2. Models of cardiac regeneration
The zebrafish, a member of the teleost family, is noted for its cardiac regenerative
capacity, and as a result is exploited throughout the field. Structurally, the zebra-
fish heart differs from that of mammals insofar as it is a two chamber organ,
consisting of one atrium and one ventricle [10,11]. As the zebrafish heart consists
of numerous small vessels for oxygen uptake rather than the large coronary vas-
culature typical of mammalian hearts, methods for inducing cardiac injury are
limited to apex resection, cryoprobe injury or genetic ablation [12–14]. Following
resection, a fibrin clot forms, providing a platform for proliferating CMs [15,16].
Remarkably, as demonstrated using a transgenic model which is deficient in ven-
tricular myoctes, atrial CMs undergo transdifferentiation and replace lost
ventricle CMs, although it should be noted that this mechanism is lost by the
age of fourmonths [17]. Interestingly, themedaka, a close relative of the zebrafish,
lacks the ability to regenerate following resection. Injured medaka hearts present
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2with persistent collagen deposition, lack of vascularization and
a limited number of proliferating CMs [18], demonstrating the
variation in evolutionary conservation of regeneration even
within closely related species.
Similar to zebrafish, axolotls are also capable of replacing
tissue following apical amputation [19,20]. Here again the
repair process begins with the formation of a blood clot
followed by CM cell cycle re-entry. The newt also retains
the ability to regenerate the heart post-resection; however,
not all CMs re-enter the cell cycle [21,22]. Moreover, replen-
ishment of CMs in the newt is initiated by tenascin-C, a
component of the extracellular matrix (ECM) [23], rather
than infiltration of resident progenitor cell populations such
as is the case with other models of regeneration. For this
reason, the newt heart is an attractive model for understand-
ing the mechanism(s) involved in CM proliferation and, more
importantly, inhibitors of this process.
Recent studies on the ability of the neonatal murine heart
to regenerate following injury would suggest that the mam-
malian heart does in fact harbour regenerative capabilities,
albeit limited to immature stages: murine hearts undergo
full regeneration post-MI from post-natal day 1 (P1), with
loss of regenerative capacity evident by P7 [24,25]. Irrespec-
tive of species differences, a common thread between the
aforementioned in vivo models is their ability to maintain
CM proliferation throughout adulthood. This mechanism is
largely lost in adult mammalian hearts, and while there are
reports of proliferating CMs [26–28], there are too few to
make any impact on the repair process.3. Epicardial signalling
A common theme with successful models of regeneration is
their ability to facilitate CM proliferation and the perfusion of
injured tissue via neovascularization, of which the epicardium
plays a central role. The epicardium contributes to heart devel-
opment through secretion of a number of factors and controlled
expression of developmental genes that have been shown to
be instrumental to normal heart development. Collectively,
these epicardial makers identify a cell population that is
capable of giving rise to cell lineages that are deemed to be epi-
cardially derived and therefore of mesothelial descent, which
goes to explain how once activated and under optimum con-
ditions the epicardium can give rise to fibroblasts, smooth
muscle cells and endothelial cells. In addition, the epicardium
has been described as a source-pool for cardiac stem cells
(CSCs) [29–32]. These unique features of the epicardium and
their respective signalling mediators will be discussed in the
following paragraphs.
(a) Wilms tumour gene
Wilms tumour gene 1 (Wt1) is a transcription factor that is
expressed in many tissues, including the urogenital system,
spleen, brain, spinal cord, mesothelial organs, diaphragm,
limb, proliferating coelomic epithelium, epicardiumand subepi-
cardial mesenchyme, during development [33,34]. Disruption
of Wt1 activity results in developmental abnormalities, and
Wt12/– mice are embryonic lethal at embryonic day 12.5
(E12.5), with heart failure being one of the contributing factors
to their early demise [33]. In the adult mammalian heart, Wt1
is reactivated following MI [35,36], although the specificity of
Wt1þ cells epicardial origin has been questioned. Wagner et al.identified Wt1þ endothelial and vascular smooth muscle cells
in the infarct and border zone, and attributed observed de
novo neogenesis to Wt1þcells activated by hypoxia [35].
In addition, Duim et al. have recently identified a population
of Wt1þ endothelial cells that undergo proliferation in a
hypoxic environment both in vitro and in vivo following MI
[37]. In contrast, Zhou et al. attribute the beneficial impact of
Wt1þ cells in infarcted hearts to paracrine signalling and
secretion of proangiogenic factors, rather than to a rise in Wt1þ
endothelial cells [36]. Despite these conflicting reports, there is
substantial evidence to show that Wt1 is activated following
injury and, once activated, contributes to angiogenesis. Fate
mapping studies have revealed Wt1 is expressed in endothelial
cells, which points to its unsuitability as an exclusive epicardial
marker. Although initially hampered by the lack of a definitive
lineage tracemodel [38], collectively these in vivo studies demon-
strate the beneficial impact of reactivating Wt1 in the adult
epicardium, and establish a link between Wt1 expression and
vascular formation.(b) Thymosin b4
The G-actin sequestering peptide thymosin b4 regulates
actin-cytoskeletal organization necessary for cell motility,
organogenesis and other cell functions. Following MI, thymo-
sin b4 has been shown to induce epicardially derived cells
(EPDCs) to form vascular precursors and prompt neo-
vasculogenesis [39,40]. Rossdeutsch et al. identified thymosin
b4 expression in embryonic endothelium, and demonstrated
that it promotes mural cell maturation and differentiation,
and embryos lacking thymosin b4 were subjected to severe
haemorrhaging (which in some cases proved to be lethal)
[39]. A follow up study by Smart et al. has demonstrated that
the addition of exogenous thymosin b4 can enhance cardiac
repair by directing Wt1þ cells to undergo cardiomyogenesis
[41], confirming earlier findings [42]. The proangiogenic effects
of thymosin b4 in the adult heart were confirmed in a study
by Shrivastava et al. [43] where mice were given a systemic
injection of thymosin b4 immediately following MI injury,
resulting in an increase in vessel density at the border zone
and remote zone, and demonstrating the global effects of
thymosin b4. In vitro data from the same study attributed the
proangiogenic effects of thymosin b4 to protein kinase C sig-
nalling and confirmed that thymosin b4 can reactivate
epicardial embryonic genes, including Wt1 and Tbx18 [43].
In addition, Rui et al. [44] have extended the cardiac
regenerative capacity of neonatal mice by pre-treatment
with thymosin b4. Here, neonatal mice were subjected to
daily intraperitoneal injections of thymosin b4 from P1 to
P7; apical resection was performed at P7, and 19 days post-
injury neonatal hearts displayed complete regeneration,
which was attributed to an increase of WT1þ cells. Notably,
post-injury mice continued to receive intraperitoneal injec-
tions of thymosin b4 on alternate days until the study was
terminated, potentially affecting the validity of the claimed
extension of the neonatal window.
Conversely, a report by Banerjee et al. failed to document any
effect of thymosin b4 on mural cell migration, angiogenesis or
embryo development. In this study, thymosin b4 knockout
models were not embryonic lethal and a lack of thymosin b4
had no impact on vascular development [45]. These contrasting
results have been attributed to variation of environment or
genetic background, resulting in differing compensatory
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strains [46]. Contrasting data on mural cell activity has also been
attributed to the different time points at whichmural cell activity
was assessed between these studies. Since thymosin b4 seems to
have a global impact on the heart, particularly in response to
injury, teasing out a specific role for this molecule is likely to gen-
erate anumberof contrastingviews. Future investigations into the
role of cardiac thymosin b4 are eagerly anticipated.
(c) Follistatin-like-1
A recent study has demonstrated the potential clinical
applicationof follistatin-like-1 (Fstl1) as a catalyst forCMreplen-
ishment [47]. Fstl1 is a secreted glycoprotein and has been
described as a cardiokine (cardiac secreted protein that can be
used as a biomarker of cardiac dysfunction). Fstl1 belongs to
the follistatin protein family, which mediate their effects by
binding to transforming growth factor b (TGFb) [48]. It is
expressed in the developing heart and in the epicardium of
the adult heart. Following either MI or ischaemic reperfusion,
Fstl1 is upregulated in murine models [49]. In addition, Fstl1
has been detected in circulation in patients with acute coronary
syndrome and protein levels are increased in failing hearts,
hence its suitability as a biomarker of cardiac dysfunction
[50,51]. The cardioprotective effects of Fstl1 have been associ-
ated with suppression of apoptosis and inflammation [49,52].
Fstl1 activates AMPK signalling, which decreases expression
of proinflammatory genes in both macrophages and CMs
in vitro, and administration of Fstl1 to damaged myocardium
reduces the expression of proinflammatory mediators in areas
of ischaemic damage in vivo [52].
In an exciting extension of these observations, epicardial
patches seeded with Fstl1 were sutured onto the mouse epicar-
dium immediately following MI injury, which resulted in
CM cell cycle re-entry and division of existing CMs [47]. Only
epicardially derived FStl1 could initiate cell division of CMs,
whereas myocardial Fstl1 did not evoke CM cell division. This
effect was specific to naive CMs (i.e. adult ventricular CMs did
not undergo cell division in response to Fstl1). Intriguingly,
this study shows that the source of Fstl1 determines its regenera-
tive (epicardial) versus cardioprotective (myocardial) potential.
Taken together, these studies shift the focus from Fstl1
as a biomarker to a viable therapeutic that is ripe for
clinical exploration.
(d) T-box genes
Several T-box family transcription factor genes have been
implicated in cardiac regeneration. Studies have demonstrated
that epicardially derived Tbx18þ cells give rise to CMs [53,54],
although it should be noted that these findings were later dis-
puted as Tbx18 was subsequently detected in the myocardium
[55]. Thus claims that newCMs solely originate from the epicar-
dium cannot be substantiated. Nevertheless, Tbx18 has been
shown to be upregulated following MI with a similar expres-
sion pattern to Wt1 [36]. Moreover, Tbx18 has been shown to
be upregulated following priming with thymosin b4 [41].
Interestingly, Tbx20 has been identified in cardiac fibro-
blasts as a key regulator of myofibroblast differentiation
[56]. Moreover, Tbx20 has been shown to regulate scar for-
mation following MI; in vivo models devoid of fibroblasts
expressing Tbx20 develop thicker scars [56]. This study high-
lights a unique role for cardiac fibroblasts in managing scar
formation following MI.(e) C/EBP
A study by Huang et al. has identified the C/EBP transcription
factor family to be key for neutrophil-mediated activation of the
epicardium following MI [57]. Disruption of C/EBP signalling
in the epicardiumblunted the inflammatory response following
ischaemic reperfusion injury, resulting in inhibition of invading
neutrophils, the net result ofwhichwas reduced scar formation.
This study offers key insights into myocardial scar and epicar-
dial communication, highlighting the fine balance between
inflammation and repair, and defining a novel role for the epi-
cardium as a modulator of the inflammatory response: an
interesting hypothesis worthy of further investigation.
( f ) Hypoxia-inducing factor
Hypoxia-inducing factor-1a (HIF-1a) is upregulated following
MI and increases vascular endothelial growth factor (VEGF)
expression in ischaemic tissues [58,59]. Furthermore, myocar-
dial overexpression of HIF-1a increases vascular density,
reduces scar formation and improves cardiac function [60]. Fol-
lowing MI, HIFs are expressed by numerous cell types,
including CMs, interstitial cells and endothelial cells [61]. Nota-
bly, HIFs have been shown to occupy distinct sites within the
epicardium that correspond with coronary vasculogenic pat-
terning [62]; this may be in conjunction with HIF-mediated
expression of Wt1 [63]. Furthermore, constituent expression
of HIF-1a in avian epicardium via a viral vector showed that
although EPDC epithelial mesenchymal transition (EMT) was
enhanced, migration of EPDCs into the myocardium was
impaired [64]. Thus, while HIF-1a may be important for driv-
ing vasculogenesis, it can also serve as a negative regulator of
EPDC migration.
(g) Retinoic acid
Epicardially derived retinoic acid (RA) synthesizing enzyme 2
(Raldh 2) is responsible for CMproliferation anddifferentiation,
aswell as ventricularmaturation andangiogenesis [65]. Further-
more, Raldh 2 plays an important role in cardiac development;
indeed, mice lacking retinoid X receptors die mid-gestation due
to detachment of the epicardium [66,67]. In adult zebrafish,
endocardial Raldh 2 has been shown to be intrinsic to repair
of the heart following resection [68]. Inhibition of RA receptors
or RA-degrading enzyme blocked the regenerative response of
the zebrafish heart [68]. Furthermore, a lack of Raldh 2
expression in the endocardium of the medaka is suggested as
a key factor for their inability to regenerate [18]. In murine
hearts, RA signalling is reactivated following MI, and may
play an important role in the repair and remodelling processes
post-ischaemic injury due to its anti-proliferative effects on car-
diac fibroblasts [69]. The use of RA as an anti-proliferative
treatment following MI is an exciting prospect for future thera-
peutic interventions; indeed, RA derivatives have been used to
suppress proliferative diseases such as prostate, lung, breast,
skin, ovarian, bladder and oral cancer [70]. Further investi-
gations are warranted to elucidate the contribution of RA
signalling to repair of the mammalian heart.
(h) Growth factors
Migration of EPDCs to the myocardium is key to regenerating
damaged myocardial tissue; therefore manipulation of myo-
cardial fibroblast growth factor (FGF) to epicardial FGF
receptor 1 (FGFR1) presents an interesting model for
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4myocardial mediated self-repair. Epicardial FGFR1 is up-
regulated following activation of myocardial FGF [71]. In
addition, overexpression of myocardial FGF results in
increased EPDC expression of FGFR [72]. Furthermore, the
FGF family has also been implicated in regeneration of the zeb-
rafish adult heart. Here, FGF 17b has been localized to the
myocardium, while FGFR2 and FGFR4 were found in the epi-
cardium [73]. These studies suggest that the expression of
FGF in the myocardium can regulate FGFR expression in the
epicardium—the result of which is epicardial cells undergoing
EMT [72,73]. Interestingly, studies on explant hearts show
that activation of FGFR is important for the migration of
proepicardial cells to the subepicardiumandmyocardium [72].
Similarly, there is evidence to support involvement of
growth factors such as platelet-derived growth factor
(PDGF) and TGFb and VEGF in myocardial to epicardial
communication. As with FGFs, PDGF and VEGF factors pro-
mote EMT and favour the fate of vasculogenesis [74,75],
while TGFb favours smooth muscle cell differentiation [76].
The other major invading cell type following MI are
macrophages, which are an abundant source of cytokines, che-
mokines and growth factors including insulin-like growth
factor 1 (IGF-1). Several studies have demonstrated the ben-
eficial impact IGF-1 has on the heart following MI [77–79];
forced cardiac-specific overexpression of IGF-1 improves car-
diac function and reduces scar formation post-MI [77].
Macrophages also secrete proangiogenic factors including
VEGF and TGFb, and have been shown to contribute to angio-
genesis post-injury [80–82]. Increasingly, macrophages are
being recognized for more than their ability to invade and pha-
gocytose debris, and indeed their ability to secrete cytokines
and chemokines at injured sites makes them an attractive pro-
spect for clinical interventions. Recently, macrophages have
been implicated in the neonatal regenerative response [83].
Although there are difficulties in determining which popu-
lations are contributing to the repair process (resident versus
circulatory), their role in the repair of the mammalian heart
merits further investigation.4. Epicardial signalling: clinical application
Providing an adequate vascular supply that can meet the meta-
bolic demands of CMs and facilitate clearing of the debris from
the immune response is a critical step towards restoring cardiac
function. Therefore, the ability to initiate angiogenesis is key to
the repair/regenerative processes. EPDCs have the ability to
differentiate to coronary lineages and the majority of paracrine
signalling from the epicardium is proangiogenic (figure 1).
Given that endogenous repair mechanism(s) in the adult
favour angiogenesis, methods to improve reperfusion should
be a primary focus of regenerative medicine, as replacement of
CMs will not be successful without the necessary infrastructure
to meet the demands of these highly metabolic cells.
To this end, the use of biomaterials such as hydrogels or
patches could have a significant impact. Here, cells are incor-
porated within a gel or patch which can then be injected or
applied to the epicardium [84–87]. In theory, cells can migrate
to the injured myocardium-secreting paracrine factors to
enhance the repair process. This approach may also have the
additive effect of activating the epicardium to secrete key fac-
tors such as Wt1, RALDH, thymosin b4 or Fstl1. Indeed, a
recent study using an IGF-1-loaded fibrin patch post-MI in aporcine model reported improved cardiac function [88].
The use of cardiac patches also has the added benefit of provid-
ing mechanical support to the weakened epicardium post-
ischaemic injury [89]. Although this approach is still in its
infancy, and considerations such as the immune response
and potential rejection of these materials need to be fully
assessed, it does seem an intriguing therapeutic avenue.5. Cardiac stem cells
The heart contains a number of distinct CSC populations;
EPDC, stem cell antigen-1 (Sca-1), c-Kit, cardiosphere-forming
CSCs and side population (SP) progenitors. Although a variety
of CSCs exist, they all share a common feature: their reported
ability to give rise to all cardiac lineages. Here, the epicardium
again plays a significant role. The epicardium itself is derived
from mesothelial cells, thus it is reasonable to assume that it
can give rise to progenitor cell types [29,42,54,90,91]. Further-
more, the reactivation of embryonic cell markers post-MI
such as Wt1 demonstrates that the epicardium retains signa-
ture gene expression patterns that are intrinsic to fetal growth
and development, and therefore potentially maintains the
necessary machinery for repair. Moreover, studies have
shown that EPDCs are capable of undergoing EMT in adult
hearts giving rise to smooth muscle cells [90].
One CSC population that has divided opinion within the
field is that of cKitþ cells, with recent investigations disputing
earlier findings that demonstrated cKitþ cells give rise to CMs.
Orlic et al. first reported that bone marrow-derived cKitþ cells
regenerate the myocardium following MI and reported cKitþ
cells as CSCs [92]. This was later disputed by Murry et al.,
who showed that cKitþ cells do not give rise to CMs [1].
Later studies confirmed these observations and went on to
claim that CMs are derived from pre-existing CMs [27]. How-
ever, a study by Ellison et al. [32] argued that cKitþ cells are
not only necessary but are sufficient to mediate repair to the
damagedmyocardium.Conclusively, a thorough investigation
using genetic lineage-tracing models demonstrated that cKitþ
cells do indeed give rise to CMs in both uninjured and injured
tissue, but at a much lower rate than previously reported [93].
With this question outstanding, the field currently errs on the
side of caution with regard to the potential of cKitþ cells as a
pool of CM precursors.
Irrespective of these discrepancies, ongoing studies are
investigating cardiospheres, essentially clusters of proliferating
mesenchymal/stromal cells that express cKit. This unique cluster
formation is thought to enhance ‘stemness’ [94]. Interestingly, as
cardiospheres diverge to a monolayer, they lose their cKit
expression. Given that cluster formation recapitulates a stem
cell-like microenvironment, it is not unreasonable to assume
that cKit plays a role in this structure formation. Post-MI, cardio-
sphere injectionhasbeenshowntobemore effective in improving
cardiac function than injections ofmonolayer cells [95]. The thera-
peutic benefits of cardiospheres over cellmonolayers is attributed
to enhanced expression of ECMand adhesionmolecules, as post-
MI these clusters are retained at the site of injury with greater
potency than injection of cells from amonolayer [94]. Thus, injec-
tion ofmulticellular spheresmayprove to be theway forward for
successful stem cell treatment.
OtherCSCs have been identified based on their expression of
Sca-1. Sca-1 is a ubiquitous stem cell marker associated
with haematopoietic stem cell lineages. In the heart, Sca-1
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Figure 1. Schematic of proposed repair following therapeutic intervention. Following ischaemic injury, the epicardium is activated following either cell injection or
application of a patch loaded with cells or growth factors, switching on fetal genes Wt1, Tbx18, RA and progenitor pools cKit Sca-1 and SP, which signal back to
damaged myocardium through the secretion of proangiogenic factors to evoke neogenesis. Activation of progenitor pools promotes CM proliferation. The net result is
reduced scar formation, increased vascular network and a new CM population. CM, cardiomyocyte; Wt1, Wilms tumour gene; RA, retinoic acid; Tbx18, T box gene 18;
EPDC, epicardially derived cell. (Online version in colour.)
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5expression is used to distinguish CSCs from differentiated cells.
The Sca-1þ population was first observed in endothelial cells
that also expressed cardiac transcription factors such as myocyte
enhancer factor 2 (Mef 2) andGATA 4 [96]. Moreover, these cells
were shown to give rise to CMs in vitro and in vivo [96,97]. Other
studieshave reported that Sca-1þ cells cangive rise toCMs, endo-
thelial cells and fibroblast cells [31,98]. Recent studies have
identified a Sca-1 population derived from endothelial lineage
that can migrate and give rise to CMs [99]. Notably, a Sca-1
gene analogue has yet to be found in the human genome and
therefore caution should be takenwhen extrapolating these find-
ings to the human heart. However, the murine Sca-1 antibody
has been used to isolate Sca-1þ cells from the human heart, pre-
sumably cross-reacting with a related peptide, and these
populationswere also found to express GATA 4 andMef 2 [100].
Further studies have led to the discovery of another
progenitor population, referred to as SP. These cells are charac-
terized by their unique ability to exclude Hoechst dye via the
ATP-binding cassette transporter [101]. The cardiac SP popu-
lation which is Sca-1þ and CD312 has been shown to be
immunophenotypically distinct from bone marrow-derived
SP population, and is capable of self-renewal and giving rise
to functionally mature CMs [102].
A recent study has demonstrated that PDGRa is necessary
for the clonogenicity of SP cells and proposes that SP cells
may be isolated based on PDGRa expression [103]. SP express
cardiac transcription factors such as GATA 4 [102], thereby
demonstrating their tendency towards cardiac-specific lineages.
Post-MI, SP cells are initially depleted but are restored again by
day 7, evidenced bya rise in the proliferationmarker Ki67 [104].
Thiswould suggest that SP cells contribute to the repair process
following MI; however, their marked depletion at the critical
24 h period could have a profound effect on the course of therepair process. Perhaps if the SP population is somehow main-
tained following the initial injury, then the loss of CMs may
be more readily appeased as the resident progenitor pools can
readily replace lost CMs (figure 1).6. Clinical application
While the evidence supports the existence of CSCs in the adult
heart, these endogenous populations are often insufficient
to repair the heart following MI. It is likely that the primary
function of these populations is to support homeostatic main-
tenance under normal physiological conditions as opposed
to mediating repair following severe injury such as MI.
Nonetheless, if it were possible to sustain these populations,
particularly 24 h post-MI, then such a repair process could
positively contribute in the face of such significant CM
depletion post-MI. Certainly, the capacity of CSCs to give rise
to various cardiac lineages is certainly a feature that needs to
be exploited. Accordingly, the method by which CSCs are
delivered to the site of injury appears to be a major influence
on their regenerative effect.
There have been many studies that demonstrate the regen-
erative effects from intramyocardial injection of stem cells
(generally bone marrow-derived) following MI [105–107].
However, translating this approach to the clinic is hampered
first by the difficulty in stem cell isolation and expansion. As
previously discussed, many parameters are used to define
CSCs, and isolating these cells is often a laborious task, with
great care needed to ensure a pure population is obtained,
although it has been demonstrated that SP cells can be effec-
tively isolated based on PDGFRa expression as opposed to
the current dye exclusion methods [103]. Second, the number
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6of cells that are successfully engrafted is often much lower than
those administered, so themechanism bywhich stem cells exert
their effects remains unclear, with varying reports of a paracrine
effect [108,109], a result of fusionwith endogenous cells [110] or
transdifferentiation [111]. Third, recent data from clinical trials
point to the ineffectiveness of stem cells, particularly bone
marrow-derived stem cells, in treatment of cardiovascular dis-
ease, with many of these trials describing a positive outcome
that was later found to be flawed by inaccurate reporting [112].
These setbacks in the clinical application of CSCs serve to
reinforce the necessity for caution when interpreting results.
However, recent clinical revelations should not impede pre-
clinical advancements being made with CSCs. Initial studies
with allogeneic cardiospheres using rodent models noted
improved cardiac function, reduced scar formation and
overall less damage to the myocardium [95]. The CADUCEUS
(cardiosphere-derived autologous stem cells to reverse ventri-
cular dysfunction) clinical trial reported similar findings and
further clinical trials are being considered [113].
Given the diverse populations that make up the heart, per-
haps a combination approach, such as that as demonstrated by
Ye et al. [88] may prove to be a more worthwhile intervention
to assist the repair process. Here, a trilineage engraftment con-
sisting of CMs, ECs and SMCs derived from human-induced
pluripotent stem cells (hiPSCs) was supported by pre-appli-
cation of an IGF-1-loaded fibrin patch. The overall result was
improved cardiac function with a greater engraftment rate
than previously reported. This study was terminated four
weeks post-cell injection; therefore, it is difficult to determine
the long-term benefits. However, it does set a precedent for
future in vivo approaches.7. Conclusion
While cardiac regeneration appears to be easily achieved by
lower vertebrates and amphibians, the adult mammalian
heart struggles to function and mediate repair simultaneously.
Until recently, the epicardium has been overlooked as being a
key player in the repair/regenerative process. Today it is the
focus of intense research, with many studies concentrating
on the stem cell potential of this region of the heart. Although
resident CSCs have been identified, the insufficiencies of
endogenous stem cell populations to alleviate acute and chronic
damage to mammalian cardiac tissue remain to be overcome.
Therapeutically speaking, identifying methods to sustain stem
cell populations during ischaemic damagemayalso prove fruit-
ful in terms of replenishing lost CMs. Moreover, combination
approaches exploiting the use of biomaterials and cell-based
therapies are making remarkable advances. In addition, there
have been various studies examining epicardial development,
and these have aided our understanding of the adult mamma-
lian heart injury response. Evidently, the epicardium is key to
mediating repair; as a signalling powerhouse and cell reservoir,
it is certainly equipped to do so. However, cardiac repair
requires a speedy and robust approach, and although advances
are being madewe are still far from contriving an ‘off the shelf’
cure for the masses affected by heart failure.
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